Centre Paul Strauss

Running trials

• Not yet recruiting

  Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

  NCT07150403· Phase 2· Source

• Recruiting

  Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging

  NCT06276465· Phase 3· Source

• Active, not recruiting

  Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer

  NCT05476796· Phase 2· Source

• Recruiting

  Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0

  NCT05476939· Phase 3· Source

• Active, not recruiting

  MSI/dMMR tumors in perioperative setting

  NCT04795661· Phase 2· Source

• Active, not recruiting

  Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy

  NCT04181203· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers1 recruiting
• Colorectal cancer1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Prostate cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Active, not recruiting

  A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

  NCT04211337· Phase 3· Source